Respiratory System Neoplasm

The POSEIDON (NCT03164616) open-label, randomized phase 3 trial included 1,013 patients with metastatic non-small-cell lung cancer (NSCLC), of whom 637 had nonsquamous histology and 612 were evaluable… (full text at CIViC)

PMID 39385035 · Skoulidis et al., 2024 · Open in CIViC

A retrospective analysis of 871 non-squamous NSCLC patients treated with chemotherapy (platinum compound plus pemetrexed) combined with immunotherapy (pembrolizumab) found that those with KEAP1 mutati… (full text at CIViC)

PMID 39385035 · Skoulidis et al., 2024 · Open in CIViC

In non–small cell lung cancer (NSCLC) models, KEAP1-mutant cell lines (H838, H460) exhibited strong sensitivity to NSC84167 (NSLC01) in MTT cell viability assays, with IC₅₀ values well below 1 µM, whi… (full text at CIViC)

PMID 34247201 · Dai et al., 2021 · Open in CIViC

Case report of a 50-year-old male with Stage 1 Lung adenocarcinoma. NGS detected the presence of KIF5B::EGFR fusion (exon 15 and exon 18). The patient received two cycles of chemotherapy but experienc… (full text at CIViC)

PMID 34163176 · Wang et al., 2021 · Open in CIViC

This case study reports the first case of a KIF5B-EGFR fusion (KIF5B exon 15–EGFR exon 18) in primary lung adenocarcinoma. The patient showed a significant partial response to afatinib and bevacizumab… (full text at CIViC)

PMID 32903808 · Xu et al., 2020 · Open in CIViC

A 56 year old woman presents with poorly differentiated stage IIIC lung adenocarcinoma. Chemoradiotherapy and 12-month durvalumab was administered with significant response. 11 months after durvalumab… (full text at CIViC)

PMID 36033470 · Lin et al., 2022 · Open in CIViC

A patient with stage IV NSCLC were treated with CDDP+PEM+Bmab, CBDCA+GEM, pembrolizumab and SAIT301 (met inhibitor). After disease progression, she was received crizotinib and exhibited a dramatic res… (full text at CIViC)

PMID 29102694 · Cho et al., 2018 · Open in CIViC

Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC)

PMID 25982012 · Subbiah et al., 2015 · Open in CIViC

In this phase 1 trial, 57 patients with RET fusion- or mutation positive cancers were treated in 7 dose levels. Among patients with RET-Fusion positive NSCLC, objective response rates were 65% (n = 17… (full text at CIViC)

Open in CIViC

We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC)

PMID 27496134 · Huang et al., 2016 · Open in CIViC

We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC)

PMID 27496134 · Huang et al., 2016 · Open in CIViC

A 61-year old patient with KIF5B-RET fusion positive NSCLC received clinical benefit from selpercatinib treatment initially. ctDNA surveillance showed the emergence of RET G810S 3 months after the sta… (full text at CIViC)

PMID 31988000 · Solomon et al., 2020 · Open in CIViC

A RET fusion-positive NSCLC patient who had been treated with multiple lines of chemotherapy and targeted therapies received selpercatinib. The patient initially tolerated selpercatinib achieving a sy… (full text at CIViC)

PMID 31988000 · Solomon et al., 2020 · Open in CIViC

We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC)

PMID 27496134 · Huang et al., 2016 · Open in CIViC

In a stage IV lung adenocarcinoma patient harboring a KIT D816G mutation, the KIT D816G mutation was associated with crizotinib resistance. The patient was initially found to harbor a ROS1 gene rearra… (full text at CIViC)

PMID 27068398 · Dziadziuszko et al., 2016 · Open in CIViC

KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer.

PMID 15217946 · Boldrini et al., 2004 · Open in CIViC

Ba/F3 cells harboring the KIT L576P mutation are sensitive to nilotinib, imatinib and lower concentrations of dasatinib.

PMID 17372901 · Antonescu et al., 2007 · Open in CIViC

In a retrospective pan-cancer analysis of four immune checkpoint therapy (ICT)–treated cohorts (melanoma n = 287; NSCLC n = 131; total n = 418), KMT2 family mutations were associated with improved ICT… (full text at CIViC)

PMID 33653367 · Zhang et al., 2021 · Open in CIViC

In preclinical lung squamous cell carcinoma models, KMT2D loss increased sensitivity to SHP2 inhibition (SHP099) and pan-ERBB inhibition (afatinib). Enhanced growth suppression was observed in Kmt2d-d… (full text at CIViC)

PMID 36525973 · Pan et al., 2023 · Open in CIViC

In preclinical lung adenocarcinoma (LUAD) models, loss-of-function KMT2D (truncating/inactivating) was associated with greater sensitivity to glycolysis inhibition, most consistently 2-deoxy-D-glucose… (full text at CIViC)

PMID 32243837 · Alam et al., 2020 · Open in CIViC

Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led… (full text at CIViC)

PMID 24836576 · Van Allen et al., 2014 · Open in CIViC

To characterize crizotinib resistant tumors, three patient cases with established MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC) samples were all found to have gained amplification of… (full text at CIViC)

PMID 30072474 · Bahcall et al., 2018 · Open in CIViC

To determine the origin of drug resistance in MET amplified cell lines, MET small-molecule inhibitors PHA-665752 or JNJ38877605 were tested in cell lines harboring MET amplification. In cell line GR15… (full text at CIViC)

PMID 20841479 · Cepero et al., 2010 · Open in CIViC

KRAS mutations in lung cancer patients are not associated with smoking history, age or gender.

PMID 18794081 · Riely et al., 2008 · Open in CIViC

There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC.

PMID 11208838 · Schiller et al., 2001 · Open in CIViC

In locally advanced or metastic (stage IIIB or IV) non-small cell lung cancer patients with KRAS mutations, those treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib … (full text at CIViC)

PMID 16043828 · Eberhard et al., 2005 · Open in CIViC

In a prospective study of 522 European non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (42/307) treated with erlotinib as a second-, third-line or more treatment were associa… (full text at CIViC)

PMID 22982650 · Cadranel et al., 2012 · Open in CIViC

In a study of 48 NSCLC patients, those with G12C or G12V mutant KRAS were associated with decreased progression free survival (1.84 months) compared with other KRAS mutants or with wild-type KRAS (3.3… (full text at CIViC)

PMID 22247021 · Ihle et al., 2012 · Open in CIViC

KRAS G12C occur more frequently in women than men.

PMID 23014527 · Dogan et al., 2012 · Open in CIViC